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Transglutaminase type 2 (TG2) (EC 2.3.2.13) is a multifunctional ubiquitous 
protein which has been implicated in the pathogenesis of many apparently unrelated 
diseases such as tissue fibrosis
1, 2, 3
, celiac disease
4
, cancers
5, 6
, neurodegenerative 
disorders
7
 and type II diabetes
8
. Although TG2 is capable of different biological 
activities, overall its expression and activation is believed to occur as a response to tissue 
injury and/or cell stress. Protein cross-linking is the enzymatic reaction for which TG2 is 
better known and depends on Ca
2+
 binding and GTP dissociation from TG2, conditions 
which are favoured in the extracellular environment or following cell injury and loss of 
Ca
2+
 homeostasis. Protein cross-linking leads to the formation of intra- or inter-molecular 
N(-glutamyl)lysine bonds between the -carboxamide group of a peptide-bound Gln 
residue and either the -amino group of a peptide-bound Lys residue or a primary amino 
group of polyamines, resulting into protein polymerisation/modification
9
. TG2 causes 
additional post-translational modifications among which protein deamidation of Gln 
residues contributes to the development of disorders caused by gluten sensitivity (e.g. 
celiac disasease)
4
.   
 
TG2-mediated protein crosslinking has been convincingly linked to normal and 
abnormal wound repair processes. General consensus exist that the externalisation of 
TG2 and activation of its cross-linking activity are responsible for extracellular matrix 
(ECM) stabilisation and resistance to matrix metalloproteinase degradation
10
, and that 
uncontrolled cross-linking as a consequence of chronic cell insult and increased secretion 
of TG2 is implicated in the pathogenesis of tissue fibrosis 
1, 2, 3
. Not all the externalised 
TG2 is believed to be enzymatically active, despite the favourable conditions of low 
Ca
2+
/GTP in the extracellular environment
11
. Most TG2 is thought to remain latent and be 
activated on demand e.g. for cell repair/proliferation in response to tissue injury/stress
12, 
13, 14
 or for modulation of the ECM
15, 16, 17
 e.g. by transforming growth factor beta
18, 19
 in 
response to oxidative stress
20, 21
 and by the hypoxia inducible factor-1 in solid tumours
22
. 
TG2 cross-linking may be controlled by the tight binding of TG2 to large substrates like 
fibronectin (FN)
23, 24
, which can further complex with collagen
25
, and by TG2 
internalisation and subsequent lysosomal degradation
26
.  In recent years it has become 
clear that the influence of TG2 on cell-matrix interactions also depends on cross-linking 
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independent mechanisms. TG2 has been ascribed an adhesive role by acting as either an 
intracellular GTPase
27
, an integrin-1 co-receptor
28
, or a structural protein supporting 
adhesion-mediated cell signalling independently from the Arg-Gly-Asp (RGD) cell 
binding domain of FN
29
. Despite the importance of TG2-externalisation for most of the 
cross-linking dependent and independent roles, the mechanism of TG2 secretion is 
elusive.  TG2 lacks a leader peptide and it is not post-translationally modified for classic 
externalisation through the endoplasmic reticulum/Golgi route
9
. Among the influencing 
factors are the requirements for TG2-active-state conformation
30, 31
 and an intact N-
terminal FN binding site
32
. 
 
Recent studies by Scarpellini et al
33
 and Telci et al
34
 published in the Journal of 
Biological Chemistry have highlighted a novel interaction of TG2 with the heparan 
sulphate proteoglycan (HSPG) syndecan-4 (S4), and suggested that this interaction may 
be important for controlling the cell-surface trafficking and cross-linking activity of 
TG2
33
, and for mediating the adhesion-dependent signalling role of matrix TG2
34
. 
 
Early work from Bergamini’s group described affinity purification by heparin-
sepharose as an effective step for TG2 purification from erythrocytes
35
. More recently, 
the involvement of cell-surface HSPGs in TG2-mediated RGD-independent cell adhesion 
was hypothesised
29
, since pre-treatment of cells with HS-degrading enzyme led to the 
disruption of this distinct cell adhesion process. This earlier work has prompted further 
investigations on the binding interaction between TG2 and heparin, a highly sulphated 
analogue of heparan sulphate (HS) glycosaminoglycan chains, which only exist 
covalently bound to the core protein of cell-surface proteoglycans e.g. syndecans, 
glypicans and secreted proteoglycans
36
. HSPGs bind extracellular ligands through the HS 
and influence their biological activity by affecting protein stability, activity, 
conformation, as well as cell-surface localisation, membrane secretion/internalisation and 
protein interactions
 36, 37
. Among the HSPG-subfamilies, the syndecans act as co-
receptors for both ECM components and soluble ligands
38
, and S4 has overlapping roles 
with extracellular TG2 in wound healing and fibrosis
39
, thus suggesting the implication of 
syndecans in the biological function of TG2. 
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The hypothesis that S4/HS could regulate TG2 was recently tested using a range 
of in vitro and cell-based approaches
33
. Initially, TG2-heparin interaction was studied at 
equilibrium by heparin/HS solid-phase assays and in real-time by surface plasmon 
resonance. The TG2-heparin/HS interaction was saturable and the apparent dissociation 
constant was in the low nM range (KD ~20 nM by solid phase and KD ~90 mM by SPR), 
suggesting high affinity of TG2 for heparin/HS, comparable to that for the classic binding 
partner FN
40
. Next, in cell systems it was established that the co-association of cell 
membrane TG2 with S4 is not mediated by FN (which binds both TG2 and HS), but 
largely depends on TG2 association with the HS chains of S4
33
 . The significance of the 
TG2-S4 interaction was then studied in primary dermal fibroblasts using a combination 
of S4 knock-out/knock-in experiments. It was shown that lack of S4/HS leads to a lower 
level of cell-surface TG2 antigen and cross-linking activity, and a parallel accumulation 
of cytosolic TG2 in primary fibroblasts but no changes in the total level of TG2 
expression. Since heparin did not have a direct regulatory effect on TG2 enzymatic 
activity
33
, this finding led to the suggestion that the HS chains of S4 may direct the cell-
surface trafficking and localization of TG2 at cell-matrix adhesions. Indeed, complexes 
of TG2 and S4 were detected at cell-matrix adhesions by immunofluorescence
33
. Hence, 
cell-surface HS may affect the externalization of TG2 in a similar way to that recently 
reported for fibroblast growth factor-2
41
. Functional inhibition of HS with surfen, a small 
antagonist of HS
42
, or heparitinase digestion led to even higher alterations in cell-surface 
TG2 activity, suggesting that more cell-surface HSPGs are likely to be implicated
33
. 
Since the endocytic receptor LRP1 responsible for TG2 internalisation has been shown to 
act in concert with HSPGs
26, 37
, the possibility of a dual function of HSPGs in TG2 
externalisation and internalisation is intriguing. However, published data so far support a 
role for HSPGs in the trafficking of TG2 to the cell-surface since S4-null fibroblasts 
display an accumulation of intracellular TG2
33
. Given the variety of roles of HS, the high 
affinity binding of TG2 for HS is likely to influence the function of TG2 widely in the 
extracellular environment. Consistent with this idea, Telci et al recently showed that once 
TG2 is externalised and bound to FN, S4 may act as a cell-surface receptor mediating the 
RGD-independent outside-in signalling role of matrix TG2 in partnership with integrin-
 5 
1
34
. The interaction of matrix TG2 with S4 has been shown to mediate activation of 
protein kinase C and its further interaction with integrin-, thus leading to activation of 
focal adhesion kinase and survival ERK1/2 mitogen activated protein kinases. This 
pathway, which is RGD-independent, relies on increased deposition of TG2 in the ECM 
e.g. by cell secretion following cell lysis or erythrocytes rupture at wound sites. Hence, 
TG2 mediated RGD-independent cell adhesion is likely to be prevalent in restricted 
conditions of matrix breakdown, accumulation of RGD peptides of FN and competitive 
block of integrin-mediated RGD-dependent pathway. It is envisaged that in these 
conditions, TG2 degradation would be limited by binding to both FN and HS
25, 10, 43
, 
hence TG2 would be able to rescue cell adhesion and facilitate wound repair. 
 
In conclusion, characterisation of the high affinity binding of TG2 to HS has 
opened the way to new hypotheses on how TG2 may be externalised and its function 
regulated in the ECM. Studies so far have led to the identification of S4 as a new 
component of the cell-surface trafficking of TG2 and a novel cell-surface receptor for 
matrix TG2. It is anticipated that the flexibility and length of the HS chains would allow 
for this dual interaction of S4 with TG2 to take place. TG2 and S4 are molecules that are 
both increased in conditions of tissue fibrosis in vivo
44, 3, 45
. If their interaction is 
confirmed in vivo, alteration of S4-TG2 association could become an attractive target for 
the control of tissue fibrosis.  
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